Press Releases July 6, 2026 08:00 AM

Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on July 6, 2026

Inspire Medical Systems to Announce Q2 2026 Financial Results on August 3 with Investor Conference Call

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
INSP

Inspire Medical Systems, a medical technology company specializing in solutions for obstructive sleep apnea, will report its second quarter 2026 financial results after market close on August 3, 2026, followed by an investor conference call. The company highlights its FDA and international approved Inspire therapy, a neurostimulation treatment for moderate to severe obstructive sleep apnea.

Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on July 6, 2026
INSP
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Scheduled release of Q2 2026 financial results on August 3, after market close.
  • Investor conference call planned to discuss financial results and business developments.
  • Inspire's therapy is FDA, EU MDR and PDMA-approved neurostimulation technology treating obstructive sleep apnea.
  • The announcement concerns the medical technology and healthcare sectors, particularly companies focusing on sleep and respiratory therapy devices.

MINNEAPOLIS, July 06, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2026 after the close of trading on Monday, August 3. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q2 2026 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Inspire's Q2 2026 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. 

Following the call, a replay will be available on the Company's Investor Relations website approximately two hours after the event and archived on the site for two weeks.

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
[email protected]
617-549-2443


Risks

  • Uncertainty about financial results which could impact investor sentiment and stock price.
  • Potential challenges in market adoption or regulatory environment changes affecting medical device companies in the sleep apnea treatment market.
  • The broader healthcare sector could be influenced by evolving reimbursement policies or competitive technologies impacting Inspire's market position.

More from Press Releases

Nasdaq Rings Opening Bell at the White House to Mark America 250 and the First Trading Day for Trump Accounts Jul 6, 2026 authID Announces 2026 Annual Shareholder Meeting Results Jul 6, 2026 Brookfield Asset Management to Host Second Quarter 2026 Results Conference Call Jul 6, 2026 Xcel Brands Announces Licensing Agreement with KBL Group for OFF/DUTY by Coco Rocha Jul 6, 2026 Correction: Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on August 3, 2026 Jul 6, 2026